Obermatt
See Similar Stocks →

Axsome Therapeutics

NMQ:AXSM · US05464T1043
PharmaceuticalsMedium

360

43
Profit price100
Owner Earnings Yield1
Dividend Yield1
Price/Sales34
EV / Gross Profit5
Price/Book1
Return on Capital1
Cash Return on Capital1
Return on Equity3
EBIT Margin1
Gross Profitability98
Accruals97
Owner Earnings Margin1
Sales growth78
Profit growth63
Reinvestment51
Price momentum74
Debt load14
Refinancing43
Debt Payback1
Liquidity39
Analyst ratings71
Opinion Changes50
Price Target Upside44
Market mood100
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Axsome Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2012
Employees903
Websiteaxsome.com
ISINUS05464T1043
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Pain ManagementAddictionNeurologySleep TechnologyPsychiatryChronic DiseasesCentral Nervous SystemBiopharmaBiotechnologyTherapeutics

Description

Axsome Therapeutics, Inc. (Axsome) operates as a biopharmaceutical company. The company develops medicines for people impacted by central nervous system (CNS) conditions. The company delivers scientific breakthroughs by identifying critical gaps in…

Analysis

Middle-of-the-road

Axsome Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
47
2026

All-time high

47

Jun 2026

All-time low

39

Mar 2026

Average rank

43

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
34
—
—
—
Price/Earnings
100
—
—
—
Price/Book
1
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
27
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Axsome Therapeutics with its peers
NRX Pharmaceuticals
NAQ:NRXP
49
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
—
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Travere Therapeutics
NMQ:TVTX
53
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Definium Therapeutics
NSQ:DFTX
22
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Esperion Therapeutics
NMQ:ESPR
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →